What's the difference between all the Covid vaccines?

First there was Pfizer, then AstraZeneca, now Moderna and Novavax. How do they differ? And which might you get?

Obs Pfizer

Pfizer/BioNTech

Approved in UK, EU and US

Type Synthetic mRNA vaccine made from enzymes; sends “messenger” RNA into body with instructions on how to produce antigens.

Manufacture Cultured cell materials made by BioNTech in Germany, then sent to Pfizer in Puurs, Belgium to be formulated and bottled. Similar process in US; and rival French firm Sanofi also making doses.

Distribution From Belgium it goes to central NHS depots, then batches of 1,000 doses sent to hospitals and GP hubs where they are thawed from -70C.

Supply Some part of England including London have received less than others. Pfizer has cut supply while it upgrades Belgian factory. Enzyme manufacturing process can be less efficient at large volumes.

Delivery UK ordered 40m doses, but will not say how many delivered. Pfizer to make 2bn this year, with 200m for EU, 170m for US. Covax, a WHO initiative, bought 40m for low-income countries.

Obs Astra Oxford

Oxford/AstraZeneca

Approved in UK and EU

Type A “viral vector” vaccine using common cold virus modified with “spike” protein to make it similar to Covid-19.

Manufacture Grown from cells infected with virus in “bioreactors”; then filtered and purified. UK plants in Wrexham, Oxford and Keele. Also in Netherlands, Belgium and Germany.

Distribution Can be kept six months in standard refrigeration. Is going to 206 hospitals, 50 regional hubs and 1,200 GP surgery hubs.

Supply Plants in Belgium and Germany have had production problems – biological processes are not always predictable. The UK Vaccine Taskforce noted “fill-finish” facilities in Wales where doses are filled in vials as signficant possible bottleneck, according to Dr Zoltán Kis, a research associate at Future Vaccine.

Delivery UK has ordered 100m doses, EU has ordered 300m, but firm will only be able to deliver 25m by end of March.

Obs Moderna

Moderna

Approved in UK, EU and US

Type MRNA vaccine made using similar process as Pfizer/BioNTech.

Manufacture American firm has two main plants in US, and set up operations in Switerland, with Lonza, and in Sweden with Recipharm.

Distribution Must be stored at -20C, so specialist vaccination centres.

Supply Moderna had production delays with shortage of glass vials and rubber stoppers.

Delivery UK has ordered 17m doses with first 5m arriving from March. US has ordered 200m, and EU 160m. Covax is in talks.

Obs Novax

Novavax

Phase 3 trial ended – not yet approved

Type A protein subunit vaccine, NVX-CoV2373, designed using part of Covid-19, and contains spike proteins produced by moth cells infected with genetically modified version of coronavirus. Also contains an “adjuvant”, which enhances immune response.

Manufacture Has signed deals with manufacturers in Germany, Czech Republic, and Fujifilm Diosynth factory in Teesside. Some ingredients will be made in India, and adjuvants made in US, Sweden and Denmark.

Distribution Can be stored at refrigeration temperatures. Yet to be approved in UK.

Supply First doses not expected until March or April. US firm is smaller than other vaccine makers and has not delivered on this scale before.

Delivery UK has ordered 60m doses.

Obs Johnsons

Johnson and Johnson

Phase 3 trial ended – not yet approved

Type Viral vector vaccine, similar to the AstraZeneca, using modified cold virus as a base.

Manufacture Firm has seven factories in US and Europe that will make 1bn doses this year.

Distribution Vaccine can be refrigerated, but not yet been approved in the UK.

Supply J&J is behind its original plan to deliver 12m doses in US by March.

Delivery UK bought 30m doses. J&J is due to deliver 100m doses to the US, 200m to EU and 500m to Covax.

Other vaccines UK has pre-ordered 60m doses each from GSK/Sanofi Pasteur and Valneva, which are in phase 2 trials.

• This article was amended on 12 February 2021 to remove a reference to a Janssen vaccine. As a subsidiary company, Janssen is developing the Johnson and Johnson vaccine.

Contributor

James Tapper

The GuardianTramp

Related Content

Article image
Pfizer and AstraZeneca ‘highly effective’ against India Covid variant
A Public Health England study has revealed the vaccines can be up to 88% effective after a second dose

Robin McKie

22, May, 2021 @6:28 PM

Article image
Two new vaccines on the way – with more to follow this year
Half of UK adults have had a first jab, and future supplies of millions of doses look assured

Robin McKie

04, Apr, 2021 @6:00 AM

Article image
Global Covid vaccine rollout threatened by shortage of vital components
Pharmaceutical firms warn of delays to items such as the large bags in which vaccine cells are grown

James Tapper

10, Apr, 2021 @2:44 PM

Article image
The Oxford Covid jab is delivered this week. But when will vaccines bring results?
Fall or rise in coronavirus cases will not initially be a good measure of efficacy, say scientists devising ways to audit progress

Robin McKie Science editor

03, Jan, 2021 @7:15 AM

Article image
UK can expect thousands of Covid deaths every year, warn scientists
Disease will circulate alongside flu and other seasonal viruses and become part of accepted winter illness

Robin McKie Observer science editor

31, Jul, 2021 @5:31 PM

Article image
New Covid variants ‘would set us back a year’, experts warn UK government
Vaccine-beating variant is ‘realistic possibility’, say scientists, amid calls for contingency plans to be revealed

Michael Savage

14, Aug, 2021 @11:01 PM

Article image
Veterinary workers cull 17 million Danish mink to halt new Covid
The animals were carrying a new strain of the virus, possibly vaccine-resistant, and infected several hundred people

Robin McKie

08, Nov, 2020 @7:45 AM

Article image
UK might not be over the worst, scientists warn, as Covid case numbers stay high
Inoculation programme must be stepped up before the onset of winter

Robin McKie

03, Oct, 2021 @6:45 AM

Article image
The two tests that will help to predict spread of Covid-19
One detects past infection, the other finds current viral load – but there’s a shortage of staff trained to carry them out

Robin McKie

29, Mar, 2020 @8:27 AM

Article image
Is vaccinating against Covid enough? What we can learn from Chile and Israel
Contrasting lessons from the two countries, both with high rates of inoculation against the virus, show the danger is not past

Robin McKie Observer science editor

11, Apr, 2021 @7:29 AM